全文获取类型
收费全文 | 60200篇 |
免费 | 3536篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 894篇 |
儿科学 | 1832篇 |
妇产科学 | 1408篇 |
基础医学 | 9050篇 |
口腔科学 | 2198篇 |
临床医学 | 5676篇 |
内科学 | 10919篇 |
皮肤病学 | 1485篇 |
神经病学 | 6464篇 |
特种医学 | 2773篇 |
外科学 | 8371篇 |
综合类 | 204篇 |
一般理论 | 32篇 |
预防医学 | 4017篇 |
眼科学 | 1171篇 |
药学 | 4049篇 |
中国医学 | 87篇 |
肿瘤学 | 3150篇 |
出版年
2023年 | 322篇 |
2022年 | 243篇 |
2021年 | 542篇 |
2020年 | 594篇 |
2019年 | 644篇 |
2018年 | 1306篇 |
2017年 | 1114篇 |
2016年 | 1453篇 |
2015年 | 1176篇 |
2014年 | 1383篇 |
2013年 | 2511篇 |
2012年 | 3181篇 |
2011年 | 3576篇 |
2010年 | 1888篇 |
2009年 | 1254篇 |
2008年 | 3565篇 |
2007年 | 3715篇 |
2006年 | 3506篇 |
2005年 | 3427篇 |
2004年 | 3323篇 |
2003年 | 3328篇 |
2002年 | 3243篇 |
2001年 | 2613篇 |
2000年 | 3288篇 |
1999年 | 1800篇 |
1998年 | 602篇 |
1997年 | 510篇 |
1996年 | 385篇 |
1995年 | 323篇 |
1994年 | 335篇 |
1993年 | 319篇 |
1992年 | 350篇 |
1991年 | 284篇 |
1990年 | 277篇 |
1989年 | 353篇 |
1988年 | 275篇 |
1987年 | 276篇 |
1986年 | 266篇 |
1985年 | 316篇 |
1984年 | 346篇 |
1983年 | 299篇 |
1982年 | 267篇 |
1981年 | 237篇 |
1980年 | 214篇 |
1979年 | 276篇 |
1978年 | 188篇 |
1977年 | 208篇 |
1976年 | 198篇 |
1975年 | 178篇 |
1973年 | 180篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
32.
33.
J. Saßmannshausen N. Bornfeld A. Kluge W. Sauerwein F. Härting A. Wessing 《International ophthalmology》1989,13(4):243-251
Advanced malignant melanomas of the uvea unsuited for an eye salvaging approach require enucleation of the tumor containing eye. A series of 68 patients is reported who underwent enucleation combined with insertion of a spherical dura-encased implant after 30 Gray pre-irridiation therapy of the orbit. Postoperative results with special attention to cosmetic outcome and motility of the prosthesis suggest that the insertion of an orbital implant should be preferred to the enucleation with no implant. 相似文献
34.
35.
Erja Wiili-Peltola Mika Kivim?ki Marko Elovainio Marianna Virtanen 《Journal of health organization and management》2007,21(2-3):320-332
PURPOSE: The purpose to clarify what kind of managerial challenges employees experience regarding organisational justice in hospitals. DESIGN/METHODOLOGY/APPROACH: This exploratory study of 8,971 employees working in 14 hospitals and examines the concept of organisational justice in management with qualitative and quantitative methods. FINDINGS: An inductive content analysis of the comments revealed five integrative frames describing challenges in hospital management at respondents' workplaces. These frames should be regarded as major managerial challenges in hospitals. These findings illustrate important antecedents of organisational justice and suggest that work units tend to share the same perceptions of justice. They also reveal that individually produced comments reflect collective experiences in organisational justice. Further, the results indicate that problems in management and policies are often experienced in a complex way, and people making justice judgements do not separate procedural and interactional factors. RESEARCH LIMITATIONS/IMPLICATIONS: Although the commentators producing qualitative data represented many organisational hierarchy levels, the results should not be generalised to apply to horizontal, informal social relationships. PRACTICAL IMPLICATIONS: This paper gives useful information regarding challenges in human resources management in hospitals. ORIGINALITY/VALUE: The paper suggests that people making fairness judgements do not make a distinction between procedural and interpersonal factors. Instead, they use any information available to judge the righteousness of the management events. This paper serves to guide hospital managers towards a better understanding of the importance of organisational justice and its collective nature. 相似文献
36.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K.-D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(3):211-252
Occupational diseases Nos. 2108 and 2110 correspond to intervertebral disc-related diseases of the lumbar spine from many years of carrying or lifting heavy loads, occupations in extreme postures of full flexion or oscillation of the whole body when seated, and which compel the cessation of all activities which are or could be the cause for the origin, exacerbation or recurrence of the disease. These occupational diseases came into force at the start of 1993, but there have been considerable problems in their implementation. The present Part I of the contribution is the result of the work of an interdisciplinary study group and contains medical criteria for the assessment of possibly strain-related clinical characteristics and the evaluation of other possible causes. Part II is to be published in Volume 4/2005 and will deal with questions related to forced cessation and to the assessment of the loss of earning ability. Agreement was reached in many areas related to the assessment of occupational claims. This should allow for evidence-based decision making in the future for the occupational diseases Nos. 2108 and 2110. 相似文献
37.
Dr. Cäsar Boeck 《Archives of dermatological research》1886,18(1):53-56
Ohne Zusammenfassung 相似文献
38.
39.
The galanin peptide family and its three receptors have with compelling evidence been implicated in several high-order physiological disorders. The co-localization with other neuromodulators and the distinct up-regulation during and after pathological disturbances has drawn attention to this neuropeptide family. In the current study we present data on receptor binding and functional response for a novel galanin receptor type 2 (GalR2) selective chimeric peptide, M1145 [(RG)2-N-galanin(2-13)-VL-(P)3-(AL)2-A-amide]. The M1145 peptide shows more than 90-fold higher affinity for GalR2 over GalR1 and a 76-fold higher affinity over GalR3. Furthermore, the peptide yields an agonistic effect in vitro, seen as an increase in inositol phosphate (IP) accumulation, both in the absence or the presence of galanin. The peptide design with a N-terminal extension of galanin(2-13), prevails new insights in the assembly of novel subtype specific ligands for the galanin receptor family and opens new possibilities to apply the galanin system as a putative drug target. 相似文献
40.
Lars von Knorring Béla G. L. Almay Jan Häggendal Folke Johansson Lars Oreland Lennart Wetterberg 《European archives of psychiatry and clinical neuroscience》1986,236(3):131-138
Summary The aim of the present study was to investigate the discriminative power of a series of variables (including determination of depressive symptomatology by means of a visual analogue scale, determination of personality traits by means of the Karolinska Scales of Personality, determination of monoamine metabolites in CSF, platelet MAO activities, serum cortisol before and after dexamethasone suppression and urinary melatonin) in differentiating (a) chronic pain patients from healthy subjects, and (b) patients with idiopathic pain syndromes from patients with neurogenic pain syndromes. Separately each of the measures gave a significant but often low contribution to the discrimination, while a combination of several measures gave a complete discrimination both between healthy subjects and patients with chronic pain syndromes and between patients with idiopathic and neurogenic pain syndromes, respectively.Supported in part by grants from the Swedish Medical Research Council (grants no. 3371, 4145 and 5740) and by a grant from Stiftelsen Söderström-Königska Sjukhemmet 相似文献